News and Announcements
Global concerns impacting the Australian market and a mixed month for TAIM Funds
- Published June 05, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Global growth fears began to take hold during May, fuelled by escalating trade tensions between China and the US. Wall Street had its worst May since 2010, with all major indices declining by greater than -6.5%. Thanks mainly to a post-election relief rally in the financial sector, the Australian share market fared better with the ASX200 managing a gain of +1.1% for the month.
Both TAIM Funds took their first step backwards for the year, with our leading Momentum Fund retreating by a modest -0.2% during the month.
Our Leveraged Fund came off its record highs this month after its extraordinary start to the calendar year. The Fund is still maintaining an outperformance of +15% in the 20 months since inception.
After a great start to the year on global share markets, investors now seem to be weighing up where to next. Growth and trade will remain critical issues, with pressure rising on interest rates in many major economies.
About TAIM Investments
TAIM Investments operates two Australian equities investment funds. Both have exhibited exceptional performance, during an initial 4-year small-scale-offering period, and now under the company’s own AFSL. Both funds have an Australian blue chip focus – portfolio of 20 ASX200 equities, long only, no short-selling or derivatives – and we use an automated quantitative approach to deliver superior performance.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
